{"id":952588,"date":"2026-04-17T15:17:45","date_gmt":"2026-04-17T19:17:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/"},"modified":"2026-04-17T15:17:45","modified_gmt":"2026-04-17T19:17:45","slug":"evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/","title":{"rendered":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>The results reinforce that Evaxion\u2019s pioneering AI platform, <\/b><br \/>\n          <b>AI-Immunology\u2122 accurately identifies and selects the most relevant vaccine targets<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting<\/b><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating that AI-Immunology\u2122 identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026.<\/p>\n<p align=\"justify\">86% of the vaccine targets included in Evaxion\u2019s personalized cancer vaccine EVX-01 trigger a tumor-specific immune response. This is a success rate much higher than what has been reported for other methods. The high number reflects a broad yet specific immune response, increasing the likelihood of strong anti-tumor effect and positive clinical outcomes.<\/p>\n<p align=\"justify\">\u201cWe are delighted with the data demonstrating again the unique capabilities of AI-Immunology\u2122 in identifying and selecting relevant vaccine targets. This is a further validation of the platform as an effective tool for developing potentially transformational treatments of cancer and other diseases,\u201d says Bigitte R\u00f8n\u00f8, CSO of Evaxion.<\/p>\n<p align=\"justify\">\n        <b>Encouraging data<\/b><br \/>\n        <br \/>In addition to the 86% success rate, the new data set includes two-year analysis showing durable vaccine-specific immune responses following EVX-01 administration. Notably, high <i>de novo<\/i> responses (86%) were observed, meaning the vaccine gives rise to a high number of novel tumor specific T cells. This potentially increases the vaccine\u2019s tumor killing ability.<\/p>\n<p align=\"justify\">Further, a positive correlation between vaccine target AI-prediction scores and the magnitude of the immune responses was demonstrated, underlining the predictive power of AI-Immunology\u2122.<\/p>\n<p align=\"justify\">The new data stems from the phase 2 trial investigating EVX-01 in combination with MSD\u2019s (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p align=\"justify\">The trial has already yielded encouraging two-year clinical data, including a 75% Objective Response Rate. Its one-year extension was successfully completed earlier this month with three-year clinical data expected to be presented in the second half of 2026.<\/p>\n<p align=\"justify\">\n        <b>AACR presentation details<\/b><br \/>\n        <br \/>Abstract title: AI-designed personalized neoantigen vaccine, EVX-01, induces durable\u00a0<i>de novo<\/i> T-cell responses in advanced melanoma patients<br \/>Poster#: 7741<br \/>Session category: Clinical research<br \/>Session title: Immune response to therapies<br \/>Location: Poster section 42<br \/>Date\/Time: April 22, 2026, at 9am-12pm CST\/16-19 CET\u00a0<br \/>Presenter: Mads Lausen Nielsen, PhD, Project Manager at Evaxion<\/p>\n<p align=\"justify\">\n        <b>About EVX-01<\/b><br \/>\n        <br \/>EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion\u2019s lead clinical asset.<\/p>\n<p align=\"justify\">Designed with our AI-Immunology\u2122 platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3HcosnByp8-qoVVrv34XRVAntZFtrN-IdSAwMwmN3midSuIcesQjgfa9EIrtb28tPWRuNaXb2Xed1QJRlEK7l-NcxLtuzu4UtoxIpmI331w=\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology\u2122. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.<\/p>\n<p align=\"justify\">With AI-Immunology\u2122 we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development<\/p>\n<p align=\"justify\">We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients\u2019 lives by providing innovative and targeted treatment options.<\/p>\n<p align=\"justify\">For more information about Evaxion, AI-Immunology\u2122 and our pipeline, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BQl_HNvNdx76oFWKQJtu5jg-pEpxruRYDFdA2wsvqAiOl_VTCqtvzrhG9gvbkQjnHpFLR5vJqgLBZkpE0GRDDg==\" rel=\"nofollow\" target=\"_blank\">website<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BgnkVe-_cAZ7SRqcpAnZSvVKXzhN5gq_yF6LANhHmNirHf8wY9vuLOtdnMNcLPlCHltYpy1xjg0VLCog9U9iJ4dotRCDR43IX_AGJwjQV9aWbFuIhyjYp5XNBPFUe1Z48wgix-1WjXF_PRgH-ED_VDzUi-Q2Vn3qWpk7i5DpdoUEAxORFxA_831CjX65uWjwNWkN1Ct7G-TjN7k6OmEHxcUIdpF6p9Ku-TAXPKQSI44=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZmZjMjk4Y2EtNjMwNS00NTU4LTllZDctM2EwODY1MTFjZDY3LTEyNjM2NDAtMjAyNi0wNC0xNy1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion\u2019s pioneering AI platform, AI-Immunology\u2122 accurately identifies and selects the most relevant vaccine targets Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating that AI-Immunology\u2122 identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026. 86% of the vaccine targets included in Evaxion\u2019s personalized cancer vaccine &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952588","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion\u2019s pioneering AI platform, AI-Immunology\u2122 accurately identifies and selects the most relevant vaccine targets Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating that AI-Immunology\u2122 identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026. 86% of the vaccine targets included in Evaxion\u2019s personalized cancer vaccine &hellip; Continue reading &quot;Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T19:17:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial\",\"datePublished\":\"2026-04-17T19:17:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/\"},\"wordCount\":934,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/\",\"name\":\"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\",\"datePublished\":\"2026-04-17T19:17:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk","og_description":"New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion\u2019s pioneering AI platform, AI-Immunology\u2122 accurately identifies and selects the most relevant vaccine targets Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating that AI-Immunology\u2122 identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026. 86% of the vaccine targets included in Evaxion\u2019s personalized cancer vaccine &hellip; Continue reading \"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T19:17:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial","datePublished":"2026-04-17T19:17:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/"},"wordCount":934,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/","name":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==","datePublished":"2026-04-17T19:17:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMyM0MDIzNzY1NDMjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxions-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion\u2019s AI-Immunology\u2122 platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952588"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952588\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}